T1AM/TAAR1 System Reduces Inflammatory Response and β-Amyloid Toxicity in Human Microglial HMC3 Cell Line

Beatrice Polini1, Caterina Ricardi1, Andrea Bertolini1

  • 1Department of Pathology, University of Pisa, 56100 Pisa, Italy.

Insights

3-iodothyronamine (T1AM) reduces neuroinflammation by inhibiting microglial activation. This thyroid hormone derivative, acting via trace amine-associated receptor 1 (TAAR1), offers a potential therapeutic strategy for neurodegenerative diseases.

Area of Science:

  • Neuroscience
  • Immunology
  • Pharmacology

Background:

  • Microglial dysfunction and neuroinflammation are central to neurodegenerative diseases (NDDs) like Alzheimer's and Parkinson's.
  • Aberrant protein aggregation in NDDs activates microglia, exacerbating neuroinflammation and oxidative stress.
  • Targeting glial activation presents a potential therapeutic avenue for neurodegeneration.

Purpose of the Study:

  • To investigate the effects of 3-iodothyronamine (T1AM) on microglial inflammatory responses.
  • To determine if T1AM can inhibit inflammation induced by lipopolysaccharide/tumor necrosis factor-alpha (LPS/TNFα) or beta-amyloid peptide 25-35 (Aβ25-35) in human microglial cells.
  • To elucidate the role of trace amine-associated receptor 1 (TAAR1) in T1AM's anti-inflammatory actions.

Main Methods:

  • Utilized human HMC3 microglial cell line.
  • Stimulated cells with LPS/TNFα or Aβ25-35 peptide.
  • Assessed inflammatory mediator levels using ELISA and qPCR assays.

Main Results:

  • T1AM significantly inhibited the release of pro-inflammatory factors (IL-6, TNFα, NF-kB, MCP1, MIP1) in response to stimuli.
  • T1AM promoted the release of the anti-inflammatory mediator IL-10.
  • The observed anti-inflammatory effects of T1AM were confirmed to be mediated by TAAR1.

Conclusions:

  • T1AM demonstrates potent anti-inflammatory effects on activated human microglial cells.
  • The T1AM/TAAR1 system represents a promising therapeutic target for managing neuroinflammation in neurodegenerative diseases.
  • Further research into T1AM's neuroprotective mechanisms in NDDs is warranted.